Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 13 | 2022 | 109 | 3.050 |
Why?
|
| Oxidoreductases | 8 | 2015 | 117 | 1.200 |
Why?
|
| Eflornithine | 4 | 2022 | 15 | 1.170 |
Why?
|
| Antineoplastic Agents | 3 | 2022 | 1070 | 0.730 |
Why?
|
| Maintenance Chemotherapy | 2 | 2020 | 10 | 0.700 |
Why?
|
| Fenretinide | 3 | 2017 | 26 | 0.600 |
Why?
|
| Ceramides | 12 | 2017 | 578 | 0.600 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 467 | 0.540 |
Why?
|
| Telomerase | 4 | 2003 | 85 | 0.500 |
Why?
|
| Microsomes, Liver | 1 | 2011 | 44 | 0.390 |
Why?
|
| Induction Chemotherapy | 2 | 2022 | 39 | 0.370 |
Why?
|
| RNA | 2 | 2022 | 171 | 0.370 |
Why?
|
| Photochemotherapy | 3 | 2017 | 59 | 0.360 |
Why?
|
| Medulloblastoma | 2 | 2022 | 24 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 444 | 0.290 |
Why?
|
| Child, Preschool | 9 | 2021 | 3187 | 0.270 |
Why?
|
| Cell Cycle | 1 | 2007 | 312 | 0.260 |
Why?
|
| Cell Line, Tumor | 8 | 2017 | 1851 | 0.260 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2017 | 624 | 0.260 |
Why?
|
| Disease-Free Survival | 4 | 2020 | 349 | 0.250 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2003 | 29 | 0.230 |
Why?
|
| Tretinoin | 1 | 2003 | 92 | 0.220 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2022 | 2 | 0.220 |
Why?
|
| Cerebellar Neoplasms | 1 | 2022 | 17 | 0.210 |
Why?
|
| Sarcoma, Ewing | 1 | 2022 | 26 | 0.210 |
Why?
|
| Brain Neoplasms | 2 | 2022 | 371 | 0.210 |
Why?
|
| Immune Evasion | 1 | 2021 | 19 | 0.200 |
Why?
|
| Survival Rate | 3 | 2021 | 1055 | 0.200 |
Why?
|
| Immunologic Factors | 1 | 2022 | 87 | 0.200 |
Why?
|
| Precipitin Tests | 1 | 2001 | 88 | 0.190 |
Why?
|
| Genomics | 1 | 2022 | 168 | 0.190 |
Why?
|
| Head and Neck Neoplasms | 3 | 2017 | 561 | 0.190 |
Why?
|
| Apoptosis | 6 | 2017 | 1641 | 0.190 |
Why?
|
| Humans | 27 | 2022 | 68549 | 0.190 |
Why?
|
| Acid Ceramidase | 2 | 2018 | 85 | 0.180 |
Why?
|
| Antibodies | 1 | 2001 | 241 | 0.180 |
Why?
|
| Immunotherapy | 1 | 2022 | 215 | 0.180 |
Why?
|
| Stem Cell Transplantation | 1 | 2019 | 58 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 332 | 0.170 |
Why?
|
| Acetates | 1 | 2018 | 74 | 0.160 |
Why?
|
| Amines | 1 | 2018 | 98 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2022 | 1341 | 0.150 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 508 | 0.150 |
Why?
|
| Sphingolipids | 2 | 2018 | 337 | 0.150 |
Why?
|
| Mesoporphyrins | 1 | 2017 | 1 | 0.150 |
Why?
|
| Fumonisins | 1 | 2017 | 14 | 0.150 |
Why?
|
| Pyridinium Compounds | 1 | 2017 | 40 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 170 | 0.140 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2017 | 99 | 0.140 |
Why?
|
| Mutation | 1 | 2021 | 1213 | 0.140 |
Why?
|
| Indoles | 2 | 2013 | 146 | 0.130 |
Why?
|
| Child | 8 | 2022 | 6401 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2015 | 331 | 0.130 |
Why?
|
| Ornithine Decarboxylase Inhibitors | 1 | 2015 | 7 | 0.130 |
Why?
|
| Adamantane | 1 | 2015 | 40 | 0.130 |
Why?
|
| Taxoids | 1 | 2015 | 41 | 0.130 |
Why?
|
| Dacarbazine | 1 | 2015 | 32 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 659 | 0.130 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2015 | 33 | 0.130 |
Why?
|
| Polyamines | 1 | 2015 | 79 | 0.130 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 3 | 0.120 |
Why?
|
| Sphingomyelin Phosphodiesterase | 3 | 2012 | 183 | 0.120 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2015 | 200 | 0.120 |
Why?
|
| Infant | 6 | 2021 | 2891 | 0.120 |
Why?
|
| Pyridines | 1 | 2015 | 261 | 0.110 |
Why?
|
| Prognosis | 4 | 2021 | 2093 | 0.110 |
Why?
|
| Female | 11 | 2022 | 38021 | 0.110 |
Why?
|
| Thiazoles | 1 | 2013 | 95 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 799 | 0.110 |
Why?
|
| Male | 11 | 2021 | 37283 | 0.110 |
Why?
|
| Veratrum Alkaloids | 1 | 2012 | 3 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2013 | 178 | 0.100 |
Why?
|
| Phenotype | 1 | 2015 | 946 | 0.100 |
Why?
|
| Hedgehog Proteins | 1 | 2012 | 38 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 4 | 2018 | 852 | 0.100 |
Why?
|
| Enzyme Activation | 3 | 2013 | 791 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 951 | 0.100 |
Why?
|
| Adolescent | 7 | 2021 | 8904 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 1745 | 0.100 |
Why?
|
| Neoplasms | 1 | 2021 | 1664 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 756 | 0.090 |
Why?
|
| Nitric Oxide | 1 | 2012 | 382 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 434 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 2 | 2022 | 41 | 0.090 |
Why?
|
| Retrospective Studies | 1 | 2022 | 7268 | 0.090 |
Why?
|
| Oxidative Stress | 2 | 2012 | 718 | 0.090 |
Why?
|
| Time Factors | 3 | 2018 | 4655 | 0.080 |
Why?
|
| Second Messenger Systems | 1 | 2008 | 53 | 0.080 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2008 | 111 | 0.080 |
Why?
|
| Sphingomyelins | 1 | 2008 | 106 | 0.080 |
Why?
|
| Mitochondrial Proteins | 1 | 2008 | 113 | 0.080 |
Why?
|
| Mitochondria | 2 | 2013 | 643 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 710 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2007 | 954 | 0.070 |
Why?
|
| Chromatography, Liquid | 1 | 2007 | 120 | 0.070 |
Why?
|
| Young Adult | 4 | 2021 | 5710 | 0.070 |
Why?
|
| DNA Primers | 1 | 2007 | 302 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2011 | 2083 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 284 | 0.070 |
Why?
|
| RNA Interference | 1 | 2007 | 266 | 0.070 |
Why?
|
| Cell Division | 1 | 2007 | 541 | 0.070 |
Why?
|
| Base Sequence | 1 | 2007 | 1015 | 0.060 |
Why?
|
| Caspase 3 | 2 | 2017 | 233 | 0.060 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2004 | 11 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 47 | 0.060 |
Why?
|
| Hypercalcemia | 1 | 2004 | 34 | 0.060 |
Why?
|
| Lung Neoplasms | 3 | 2001 | 1172 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2007 | 1200 | 0.060 |
Why?
|
| Adult | 6 | 2021 | 21379 | 0.060 |
Why?
|
| Animals | 4 | 2015 | 20880 | 0.050 |
Why?
|
| Placenta Growth Factor | 1 | 2022 | 12 | 0.050 |
Why?
|
| Rats | 1 | 2011 | 5300 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3256 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 151 | 0.050 |
Why?
|
| Cholic Acids | 1 | 2001 | 8 | 0.050 |
Why?
|
| Adenocarcinoma | 2 | 2001 | 475 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2020 | 7028 | 0.050 |
Why?
|
| Mercaptopurine | 2 | 2014 | 9 | 0.050 |
Why?
|
| Vincristine | 2 | 2014 | 44 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2015 | 334 | 0.050 |
Why?
|
| Standard of Care | 1 | 2020 | 22 | 0.050 |
Why?
|
| Prednisone | 2 | 2014 | 104 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2001 | 700 | 0.050 |
Why?
|
| Methotrexate | 2 | 2014 | 91 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 164 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 5 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 38 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2003 | 1034 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2001 | 562 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2001 | 614 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 145 | 0.040 |
Why?
|
| Doxorubicin | 2 | 2014 | 231 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2018 | 80 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1054 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 563 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 420 | 0.040 |
Why?
|
| Mice | 3 | 2015 | 8474 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2018 | 397 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 791 | 0.040 |
Why?
|
| Caspase Inhibitors | 1 | 2017 | 36 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 35 | 0.040 |
Why?
|
| Ornithine Decarboxylase | 1 | 2015 | 17 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 64 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 34 | 0.030 |
Why?
|
| Cell Line | 2 | 2010 | 1752 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 2015 | 76 | 0.030 |
Why?
|
| Safety | 1 | 2015 | 145 | 0.030 |
Why?
|
| Vinblastine | 1 | 2014 | 40 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 304 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1140 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2013 | 1663 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2015 | 117 | 0.030 |
Why?
|
| Annexin A5 | 1 | 2013 | 16 | 0.030 |
Why?
|
| Propidium | 1 | 2013 | 26 | 0.030 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2013 | 24 | 0.030 |
Why?
|
| Caspase 9 | 1 | 2013 | 31 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 2013 | 22 | 0.030 |
Why?
|
| Dasatinib | 1 | 2013 | 17 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 240 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2013 | 134 | 0.030 |
Why?
|
| Patient Safety | 1 | 2015 | 202 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 195 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 652 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 498 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2013 | 164 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 948 | 0.030 |
Why?
|
| Smoothened Receptor | 1 | 2012 | 10 | 0.030 |
Why?
|
| Reducing Agents | 1 | 2012 | 5 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2013 | 168 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 37 | 0.030 |
Why?
|
| Culture Media | 1 | 2012 | 155 | 0.030 |
Why?
|
| Sulfhydryl Compounds | 1 | 2012 | 73 | 0.020 |
Why?
|
| Cell Count | 1 | 2012 | 248 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 2004 | 0.020 |
Why?
|
| Sphingosine | 1 | 2013 | 315 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1174 | 0.020 |
Why?
|
| Biopsy | 1 | 2013 | 539 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 167 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 447 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 1329 | 0.020 |
Why?
|
| Protein Stability | 1 | 2010 | 89 | 0.020 |
Why?
|
| Transfection | 2 | 2001 | 782 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2008 | 75 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 92 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2008 | 155 | 0.020 |
Why?
|
| Sphingosine N-Acyltransferase | 1 | 2008 | 62 | 0.020 |
Why?
|
| Protein Transport | 1 | 2008 | 280 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 3703 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 682 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2005 | 18 | 0.020 |
Why?
|
| Cytarabine | 1 | 2005 | 44 | 0.020 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2004 | 8 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2004 | 110 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 2222 | 0.010 |
Why?
|
| Cycloheximide | 1 | 2001 | 50 | 0.010 |
Why?
|
| Ubiquitins | 1 | 2001 | 22 | 0.010 |
Why?
|
| Genes, myc | 1 | 2001 | 26 | 0.010 |
Why?
|
| Half-Life | 1 | 2001 | 96 | 0.010 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2001 | 11 | 0.010 |
Why?
|
| Phosphatidylserines | 1 | 2001 | 22 | 0.010 |
Why?
|
| Daunorubicin | 1 | 2001 | 20 | 0.010 |
Why?
|
| Glucosyltransferases | 1 | 2001 | 28 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2001 | 39 | 0.010 |
Why?
|
| G1 Phase | 1 | 2001 | 42 | 0.010 |
Why?
|
| Luciferases | 1 | 2001 | 105 | 0.010 |
Why?
|
| Glucosylceramides | 1 | 2001 | 32 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2001 | 191 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2001 | 90 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2001 | 489 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2001 | 282 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 1860 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2001 | 524 | 0.010 |
Why?
|